Product development strategy

Vectura’s product development strategy is to combine its proprietary inhaler device and formulation technologies with existing off-patent or clinically validated drugs.  Inhalation is used as an improved, more effective route of delivery in order to re-purpose drugs to treat new indications, or to treat the same indication with inhalation as an improved, more effective means of delivery.

Using this approach, the product development times, costs and risks associated with early stage drug development are significantly reduced and a strong proprietary position is created.

Vectura has a significant track record in the successful management of pharmaceutical development programmes. The company’s scientists have access to a wide range of modern, Good Manufacturing Practice (GMP) processing and analytical equipment at its facilities in Chippenham and Cambridge. Vectura works in conjunction with pre-clinical, clinical and regulatory experts as well as CROs in the development of its products.